280. MULTI-OMIC FEATURES OF OESOPHAGEAL ADENOCARCINOMA PATIENTS PRE-TREATED WITH PREOPERATIVE NEOADJUVANT THERAPY
Marjan Mojtabavi Naeini(QIMR Berghofer Medical Research Institute), Nicola Waddell(QIMR Berghofer Medical Research Institute), Louise Nott(Royal Hobart Hospital), Matthew Burge(Royal Brisbane and Women's Hospital), Olga Kondrashova(QIMR Berghofer Medical Research Institute), B. Mark Smithers(The University of Queensland), Jarad Martin(Calvary Mater Newcastle Hospital), Vanessa Lakis(The University of Queensland), Val Gebski(The University of Sydney), Lauren G. Aoude(Translational Research Institute), John V. Pearson(The University of Queensland), Kate Wilson(The University of Sydney), Robert Bohmer, Janine Thomas, Vanessa Bonazzi(QIMR Berghofer Medical Research Institute), Stephen P. Ackland(Mater Misericordiae Hospital), Guy Lampe(Princess Alexandra Hospital), Conrad Leonard(QIMR Berghofer Medical Research Institute), Scott Wood(The University of Queensland), Timothy Price(Basil Hetzel Institute), Felicity Newell(QIMR Berghofer Medical Research Institute), Kalpana Patel(The University of Queensland), Christos S. Karapetis(Clínica Alemana), Venkateswar Addala(QIMR Berghofer Medical Research Institute), Sandra Brosda(The University of Queensland), Andrew P. Barbour(Princess Alexandra Hospital), Lambros T. Koufariotis(QIMR Berghofer Medical Research Institute), Euan Walpole(The University of Queensland), Robert J. Finch(Royal Brisbane and Women's Hospital), Rebecca L. Johnston(QIMR Berghofer Medical Research Institute), Jenny Shannon(Nepean Hospital), Kátia Nones(QIMR Berghofer Medical Research Institute), Elizabeth Barnes(The University of Sydney), Sowmya Sharma(The University of Queensland), Qinying Xu(The University of Melbourne), Oliver Holmes(QIMR Berghofer Medical Research Institute), David I. Watson(Townsville Hospital), John Simes(The University of Sydney), John Zalcberg(Monash Health)
Cited by 0
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k